Results 41 to 50 of about 25,691 (210)

The suppression of DNA repair induced by PARP-1 inhibitors rucaparib and olaparib in combination with the radiopharmaceutical 131I-MIBG in noradrenaline transporter-expressing xenograft tumors [PDF]

, 2018
No abstract ...
Gaze, Mark N., Mairs, Robert J., Nile, Donna L., Nixon, Colin, Rae, Colin   +4 more
core   +1 more source

Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report

Case Reports in Oncology
Introduction: Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse
Davien Deraedt, Saartje Verfaillie, Jokke Wynants, Kristof Cuppens   +3 more
doaj   +1 more source

Triggering of Suicidal Erythrocyte Death by Topotecan

Cellular Physiology and Biochemistry, 2015
Background/Aims: The topoisomerase I inhibitor topotecan is used as treatment of various malignancies. The substance is effective by triggering tumor cell apoptosis. In analogy to apoptosis of nucleated cells, erythrocytes may enter eryptosis, a suicidal
Rosi Bissinger, Ghada Bouguerra, Katja Stockinger, Salem Abbès, Florian Lang   +4 more
doaj   +1 more source

PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]

, 2015
Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T, BENEDETTI PANICI, PIERLUIGI, CASORELLI, ASSUNTA, DI DONATO, VIOLANTE, DOMENICI, LAVINIA, GASPARRI, MARIALUISA, IMPERIALE, LUDOVICA, MARCHETTI, CLAUDIA, MONTI, Marco, MUSELLA, ANGELA, MUZII, LUDOVICO, PALAIA, INNOCENZA, PECORINI, Francesco, RUSCITO, ILARY, SALERNO, LAURA   +14 more
core   +1 more source

Hyaluronic acid–targeted topotecan liposomes improve therapeutic efficacy against lung cancer in animals

Frontiers in Oncology
Lung cancer, as a serious threat to human health and life, necessitating urgent treatment and intervention. In this study, we prepared hyaluronic acid (HA)-targeted topotecan liposomes for site-specific delivery to tumor cells.
Gangqiang Xue, Lu Tang, Xinyan Pan, Sanni Li, Juan Zhao   +4 more
doaj   +1 more source

Therapeutic uses of topotecan for thoracic malignancies

Oncology Reviews, 2011
Topotecan, a topoisomerase 1 inhibitor (topo1-i), is a semi-synthetic derivative of camptothecan with wellestablished cytotoxic properties. It is licensed for the treatment of relapsed, sensitive small cell lung cancer (SCLC) and for second line ...
Saoirse O. Dolly, Craig P. Carden, James S. Myerson, Martina Puglisi, Mary E. O’Brien   +4 more
doaj   +1 more source

Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma [PDF]

, 2015
PURPOSE:To assess in vitro cytotoxic activity and antiangiogenic effect, ocular and systemic disposition, and toxicity of digoxin in rabbits after intravitreal injection as a potential candidate for retinoblastoma treatment.METHODS:A panel of two ...
Abramson, David, Arana, Eloisa, Buitrago, Emiliano, Chantada, Guillermo Luis, Croxatto, Juan Oscar, del Sole, Maria Jose, Djaballah, Hakim, Francis, Jasmine, Laurent, Viviana Eunice, Mena, Hebe Agustina, Negrotto, Soledad, Schaiquevich, Paula Susana, Sgroi, Mariana, Winter, Ursula Andrea   +13 more
core   +2 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. [PDF]

, 2016
Synovial sarcoma is an aggressive soft tissue sarcoma genetically defined by the fusion oncogene SS18-SSX. It is hypothesized that either SS18-SSX disrupts SWI/SNF complex inhibition of the polycomb complex 2 (PRC2) methyltransferase Enhancer of Zeste ...
Choy, Edwin, Cote, Gregory M, Duan, Zhenfeng, Gao, Yan, Hornicek, Francis J, Mankin, Henry J, Shen, Jacson K   +6 more
core   +2 more sources

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source